Simulations Plus Releases DDDPlus(TM) 2.0; Extensive Improvements Greatly Enhance Functionality of First-of-Kind Software
Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released version 2.0 of its DDDPlus(TM) software product. DDDPlus (Dose Disintegration and Dissolution Plus) is unique software for pharmaceutical formulation research scientists that enables them to predict how changes in drug formulation or changes in experimental setup are likely to affect dissolution rate. Dissolution rate is a critical parameter in the development of drug dosage forms, in making generic versions of existing drugs, and in quality control for production.
Dr. Michael Bolger, director of life sciences for Simulations Plus, said: “DDDPlus was dramatically improved as a result of feedback provided to us by over 60 pharmaceutical researchers who evaluated version 1.0. The program now enables formulation scientists to optimize the design of laboratory dissolution experiments to better match what happens in humans, and it now incorporates polymer matrix controlled release formulations employing both swellable and nonswellable matrices. In addition, we have improved the library of buffer compositions, added surfactant effects, and improved the execution speed and user convenience of the software.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “We released DDDPlus 1.0 about a year ago. It remains today the only software of its kind — a new venture that we hoped would add a valuable tool for formulation scientists to reduce the number of lengthy and costly ‘cut-and-try’ attempts when designing new drug formulations. Although sales were low for that version, we received important feedback from the initial evaluators, with a ‘to do’ list to make the program more effective in their ongoing research. We have now incorporated every feature that was requested, and we have added additional functionality such as the ability to simulate the rate of drug release from tablets which include special polymers that provide time-release. We’ve been showing beta versions of DDDPlus 2.0 for the last few months at numerous customer sites, with enthusiastic response. DDDPlus 2.0 is priced at a point so it is affordable to both small and large companies in the pharmaceutical industry and we expect it to be well accepted within the community of formulation scientists.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our Web site at www.simulations-plus.com .
